Inflammatory biomarkers in the evaluation of two-year  outcomes  of omalizumab treatment in severe allergic asthma.

J. Hermanowicz-Salamon (Warsaw, Poland), P. Nejman-Gryz (Warsaw, Poland), R. Rubinsztajn (Warsaw, Poland)

Source: International Congress 2018 – Biomarkers for evaluating asthma
Session: Biomarkers for evaluating asthma
Session type: Thematic Poster
Number: 1090
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Hermanowicz-Salamon (Warsaw, Poland), P. Nejman-Gryz (Warsaw, Poland), R. Rubinsztajn (Warsaw, Poland). Inflammatory biomarkers in the evaluation of two-year  outcomes  of omalizumab treatment in severe allergic asthma.. 1090

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: